Anti-TNF therapy and malignancy in patients with rheumatoid arthritis : studies on cancer incidence, recurrence and survival
Author: Raaschou, Pauline
Date: 2014-09-19
Location: Rehabsalen Norrbacka S2:01, Karolinska Universitetssjukhuet i Solna
Time: 09.00
Department: Inst för medicin, Solna / Dept of Medicine, Solna
View/ Open:
Thesis (2.496Mb)
Abstract
Tumor necrosis factor i nhibitors (TNFi) h ave become a backbone treatment of rheumatoid arthritis (RA). TNF has multiple and incompletely understood functions in tumor biology, and cancer is considered a potential adverse event of TNFi treatment. The overarching aim of this thesis was to investiga te the risk - benefit balance in RA - patients treated with TNFi, focusing on skin cancer, breast cancer progress and post - cancer survival. To put the risks into context we also contrasted RA - patients never treated with biological drugs (biologics - naïve) to th e general population. We used data from medical files, national health and census registers and the RA quality of care register, to define clinically relevant subsets of RA and cancer - related outcomes among them .
In study I we investigated the risk o f malignant melanoma and all - site cancer in TNFi - treated RA - patients (1998 - 2010), biologics - naïve RA - patients, and matched general population comparators. We detected a 50% increased risk of invasive malignant melanoma, but no increased risk of in situ mel anoma or all - site cancer among TNFi - treated compared to biologics - naïve RA - patients.
In study II we investigated the risk of non squa mous cell cancer (SCC, 1998 - 2011 ) and b asal cell cancer (BCC, 2004 - 2011 ) in TNFi - treated RA - patients, biologics - naïve RA - pa tients, and matched general population comparators. We found a 20% increase in risk of in situ SCC among TNFi - treated compared to biologics - naïve RA - patients, but no increased risk of BCC. In biologics - naïve RA - patients, we detected a doubled risk of SCC, and a 20% increased risk of BCC compared to the general population .
In study III we investigated the risk of breast cancer recurrence in 120 female RA - patients who started TNFi treatment (1999 - 2010) on average a decade after diagnosis of breast cancer. As comparator we used 120 biologics - naïve RA - patients with a history of breast cancer, matched on sex, age, year and cancer stage at diagnosis, and residency. We found no difference in risk of recurrent breast cancer and all - cause mortality between the two g roups, after adjusting for breast cancer related prognostic factors.
In study IV we investigated the clinical stage at diagnosis, and post - cancer survival of cancers developing during or after TNFi treatment (1999 - 2007), compared to cancers among biologics - naïve RA - patients. We used both a matched and an unmatched approach. No major differences in cancer stage at diagnosis or in post - cancer survival were observed among TNFi - treated RA - patients, compared to biologics - naïve RA - patients with cancer.
In study I we investigated the risk o f malignant melanoma and all - site cancer in TNFi - treated RA - patients (1998 - 2010), biologics - naïve RA - patients, and matched general population comparators. We detected a 50% increased risk of invasive malignant melanoma, but no increased risk of in situ mel anoma or all - site cancer among TNFi - treated compared to biologics - naïve RA - patients.
In study II we investigated the risk of non squa mous cell cancer (SCC, 1998 - 2011 ) and b asal cell cancer (BCC, 2004 - 2011 ) in TNFi - treated RA - patients, biologics - naïve RA - pa tients, and matched general population comparators. We found a 20% increase in risk of in situ SCC among TNFi - treated compared to biologics - naïve RA - patients, but no increased risk of BCC. In biologics - naïve RA - patients, we detected a doubled risk of SCC, and a 20% increased risk of BCC compared to the general population .
In study III we investigated the risk of breast cancer recurrence in 120 female RA - patients who started TNFi treatment (1999 - 2010) on average a decade after diagnosis of breast cancer. As comparator we used 120 biologics - naïve RA - patients with a history of breast cancer, matched on sex, age, year and cancer stage at diagnosis, and residency. We found no difference in risk of recurrent breast cancer and all - cause mortality between the two g roups, after adjusting for breast cancer related prognostic factors.
In study IV we investigated the clinical stage at diagnosis, and post - cancer survival of cancers developing during or after TNFi treatment (1999 - 2007), compared to cancers among biologics - naïve RA - patients. We used both a matched and an unmatched approach. No major differences in cancer stage at diagnosis or in post - cancer survival were observed among TNFi - treated RA - patients, compared to biologics - naïve RA - patients with cancer.
List of papers:
I. Pauline Raaschou, Julia F Simard, Marie Holmqvist, Johan Askling for the ARTIS study group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population-based prospective cohort study from Sweden. BMJ. 2013 Apr; 346, fl939.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Pauline Raaschou, Julia F Simard, Charlotte Asker-Hagelberg, Johan Askling for the ARTIS study group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of squamous cell and basal cell skin cancer- a nationwide population-based prospective cohort study from Sweden. [Manuscript]
III. Pauline Raaschou, Thomas Frisell, Johan Askling for the ARTIS study group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis - a nationwide cohort study. Ann Rheum Dis. 2015 Dec;74(12):2137-43.
Fulltext (DOI)
Pubmed
IV. Pauline Raaschou, Julia F Simard, Martin Neovius, Johan Askling for the ARTIS study group. Does cancer that occurs during or after anti-TNF therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologics. Arthritis & Rheumatism. 2011 Jul; 63(7):1812-22.
Fulltext (DOI)
Pubmed
View record in Web of Science®
I. Pauline Raaschou, Julia F Simard, Marie Holmqvist, Johan Askling for the ARTIS study group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population-based prospective cohort study from Sweden. BMJ. 2013 Apr; 346, fl939.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Pauline Raaschou, Julia F Simard, Charlotte Asker-Hagelberg, Johan Askling for the ARTIS study group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of squamous cell and basal cell skin cancer- a nationwide population-based prospective cohort study from Sweden. [Manuscript]
III. Pauline Raaschou, Thomas Frisell, Johan Askling for the ARTIS study group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis - a nationwide cohort study. Ann Rheum Dis. 2015 Dec;74(12):2137-43.
Fulltext (DOI)
Pubmed
IV. Pauline Raaschou, Julia F Simard, Martin Neovius, Johan Askling for the ARTIS study group. Does cancer that occurs during or after anti-TNF therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologics. Arthritis & Rheumatism. 2011 Jul; 63(7):1812-22.
Fulltext (DOI)
Pubmed
View record in Web of Science®
Institution: Karolinska Institutet
Supervisor: Askling, Johan
Issue date: 2014-08-29
Rights:
Publication year: 2014
ISBN: 978-91-7549-652-8
Statistics
Total Visits
Views | |
---|---|
Anti-TNF ...(legacy) | 952 |
Anti-TNF ... | 292 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Anti-TNF ... | 1 | 3 | 3 | 2 | 2 | 1 | 0 |
File Visits
Views | |
---|---|
Thesis_Pauline_Raaschou.pdf(legacy) | 592 |
Thesis_Pauline_Raaschou.pdf | 240 |
Thesis_Pauline_Raaschou.pdf(legacy) | 3 |
Thesis_22 aug_ KI.pdf(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 325 |
China | 216 |
Sweden | 206 |
Germany | 59 |
United Kingdom | 26 |
Canada | 15 |
South Korea | 13 |
Spain | 9 |
Finland | 9 |
France | 9 |
Top cities views
Views | |
---|---|
Shenzhen | 106 |
Stockholm | 58 |
Ashburn | 54 |
Sunnyvale | 35 |
Beijing | 34 |
Kiez | 20 |
New York | 12 |
Seoul | 12 |
Woodbridge | 7 |
Dublin | 6 |